Biomaterials for Cardiovascular Regeneration

Timeslot: Wednesday, April 11, 2018 - 1:00pm to 3:00pm
Track: Tissue Engineering
Room: Grand Ballroom C


In recent years, significant effort has been devoted to developing efficient therapeutic strategies for repair and regeneration of cardiovascular injures. In this regard, biomaterials have played an imperative role in successful delivery of cells and therapeutic compounds as well as in engineering of native like cardiovascular tissue substitutes. To develop proper treatment strategies for CVD, some of the challenges include vascularization of synthetic tissues, renewable cell sources, biomaterials that have similar features to the native cardiovascular tissues, and efficacy in preclinical models. In this session, we will include topics ranging from emerging biomaterials, strategies of vascularization of engineered constructs, and advances in cardiovascular tissue engineering that have shown progress in preclinical settings.


  • 1:00 p.m. 9. Invited Speaker: Ngan Huang,PhD, Stanford University

  • 1:30 p.m. 10. Predicting Cardiac Reprogramming Outcomes on Biomaterials via Systems Biology, Y. Kong*(1), A. Rioja(1), X. Xue(1), Y. Sun(2), J. Fu(1), A. Putnam(1); (1)University of Michigan, Ann Arbor, MI, (2)University of Massachusetts Amherst, Amherst, MI

  • 1:45 p.m. 11. Novel Peptide Combinations Support Dynamic Adhesion of Endothelial Colony Forming Cells, Y Tian*, W Seeto, E Lipke; Auburn University, Auburn, AL

  • 2:00 p.m. 12. Stretchable ECM membrane enhances stem cell delivery for post-MI cardiovascular repair, K. Park*(1), I. Kim(1), M. Hwang(2), D. Choi(3); (1)Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea, (2)Cornelll University, Ithaca, NY, (3)Yonsei University Health System, Seoul, Republic of Korea

  • 2:15 p.m. 13. Modulating Targeting to Ischemic Muscle with Enzyme-Responsive Nanoparticles, J. Ungerleider*(1), J. Kammeyer(1), R. Braden(1), N. Gianneschi(2), K. Christman(1); (1)University of California, San Diego, La Jolla, CA, (2)Northwestern University, Evanston, IL

  • 2:30 p.m. 14. Platelet-mimicking Therapeutic Nanoparticles for Enhanced Cardiac Repair After Ischemia-Reperfusion Injury, T. Su*(1), K. Huang(1), H. Ma(2), H. Liang(1), P. Erb(1), L. Qiao(1), D. Shen(1), M. Hensley(1), A. Young(1), T. Allen(1), A. Vandergriff(1), P. Dinh(1), J. Cores(1), J. Liu(2), L. Qian(2), F. Ligler(1), K. Cheng(1); (1)North Carolina State University, Ra

  • 2:45 p.m. 15. ROS, pH and temperature responsive hydrogels for stem cell therapy, H. Niu*, X. Hu, Z. Huang, Z. Fan, Y. Dang, C. Li, J. Guan; The Ohio State University, Columbus, OH

Invited Speaker(s)

  • Ngan Huang, PhD

Cancer Nanotechnology

Timeslot: Wednesday, April 11, 2018 - 1:00pm to 3:00pm
Track: Biomaterials for Immunity and Cancer
Room: 210/211


The cellular and therapeutic aspects of nanotechnology as it applies to the cancer will be covered under this session. The session would solicit abstracts from the biomaterial community working on the application of nano-biomaterial technologies to cancer. Nanomaterials used for the detection and treatment of cancer affect the translation of nanotechnology for cancer therapy. The field of nanotechnology translates clinically into the field of nanomedicine. Thus, the field of nanomedicine is affected by upcoming nanotechnologies although may not be directly covered by this session. Cancer detection at the nanoscale requires nanotechnologies such as quantum dots and these types of technologies are covered by this session. The cellular and extracellular make-up of cancer and its milieu detection, characterization, and treatment as linked to nanotechnologies are applicable areas for this session.


  • 1:00 p.m. 40. Disrupting Physical Interactions Between Multiple Myeloma and the Bone Marrow Niche via Nanoparticle-Mediated RNAiDisrupting Physical Interactions Between Multiple Myeloma and the Bone Marrow Niche via Nanoparticle-Mediated RNAi, M Mitchell*(1), R Langer(2); (1)University of Pennsylvania, Philadelphia, PA, (2)MIT, Cambridge, MA

  • 1:15 p.m. 41. Targeted combinatorial drug delivery using stimuli-responsive mesoporous silica nanoparticles for pancreatic ductal adenocarcinoma therapy, M Tarannum*, J Vivero-Escoto; University of North Carolina at Charlotte, Charlotte, NC

  • 1:30 p.m. 42. Targeted anti-angiogenesis therapy for cancer treatment, Y Li*, C Mao; University of Oklahoma, Norman, OK

  • 1:45 p.m. 43. T Cell-Engaging Self-Assembled Bispecific Antibody Nanoparticles Against Breast Cancer Cells, W Lv*, J Champion; Georgia Institute of Technology, Atlanta, GA

  • 2:00 p.m. 44. Nanoparticles Coated with Frizzled7 Antibodies Enable Multivalent Binding for Enhanced Wnt Signaling Inhibition in Triple-Negative Breast Cancer, R. Riley, E. Day*; University of Delaware, Newark, DE

  • 2:15 p.m. 45. Using Nucleic Acids to Target Nanoparticles to Drug-Eluting Gels for Local Drug Release, Y. Brudno*(1), E. Silva(2), C. Kearney(3), M. Aizenberg(4), D. Mooney(5); (1)North Carolina State University, Raleigh, NC, (2)UC Davis, Davis, CA, (3)Royal College of Surgeons in Ireland, Dublin, Ireland, (4)Wyss Institute, Harvard University, Cambridge,

  • 2:30 p.m. 46. Nano-Bio Interactions to Enhance the Systemic Circulation Time and Tumor Targeting Efficiency of Nanomedicine in Cancer, S. Kesharwani*(1), P. Muley(1), A. Ukidve(2), G. Bhat(1), S. Mitragotri(2), H. Tummala(1); (1)South Dakota State University, Brookings, SD, (2)Harvard John A. Paulson School of Engineering and Applied Sciences, Cambridge, MA

  • 2:45 p.m. 47. TRAIL-coated Leukocytes to Kill Tumor Cells in the Blood of Prostate Cancer Patients, N. Ortiz Otero*(1), J. Marshall(2), E.M Messing(3), D.M. Sahasrabudhe(3), M.R. King(1); (1)Vanderbilt University, Nashville, TN, (2)Cornell University, Ithaca, NY , (3) University of Rochester Medical Center, Rochester, NY

Dental/Craniofacial Materials SIG

Timeslot: Wednesday, April 11, 2018 - 1:00pm to 3:00pm
Track: Dental/Orthopaedic Biomaterials
Room: 206/207


The Dental/Craniofacial Materials SIG session focuses on the basic, applied, and clinical research of innovative biomaterials ranging from synthetic to biological origins. These bio-inspired materials are designed to repair dental/craniofacial tissue structures, restore their functions, and/or regenerate these tissues using tissue engineering approaches. Recent advances in dental biomaterial technologies include advanced bio-inspired inorganic, organic, and composite nanomaterials, controlled drug delivery strategies, surface modification, and 3D printing technology.


  • 1:00 p.m. 24. Accelerated Degradation Evaluation of Methacrylate Dental Resins, J. Sun*, X. Wang; American Dental Association Foundation, Gaithersburg, MD

  • 1:15 p.m. 25. Evaluation of Surface Morphology, Antibacterial Efficacy, and Biocompatibility of Dental Cements in Simulated Oral Environment, S Gallegos*, S Parsaei, J Marvin, D Rodrigues; The University of Texas at Dallas, Richardson, TX

  • 1:30 p.m. 26. Regeneration of tubular dentin using bio-inspired 3D micropattern, C. Ma*, X. Liu, B. Chang; Texas A&M University, College of Dentistry, Dallas, TX

  • 1:45 p.m. 27. Novel Hybrid Adhesive Designed with Buffering Capabilities and Autonomous Strengthening, P Spencer*, Q Ye, A Misra, C Tamerler; University of Kansas, Lawrence, KS

  • 2:00 p.m. 28. Efficacy of Nitric Oxide-Releasing Hyperbranched Polymers against Ex Vivo Multispecies Dental Biofilms, L. Yang*(1), F. Teles(2), L. Martin(1), S. Dua(1), M. Schoenfisch(1); (1)University of North Carolina at Chapel Hill, Chapel Hill, NC, (2)University of Pennsylvania, Philadelphia, PA

  • 2:15 p.m. 29. Reliability of dental zirconia: effect of thermal history and grain size, I. Denry*, M. Abdelaal, J. Holloway; University of Iowa, Iowa City, IA

  • 2:30 p.m. 30. Investigation of Titanium Oxide Characteristics on Healing Abutments: Retrieval Characterization and Soft Tissue Compatibility, S. Wheelis*(1), A. Montaño(1), M. Quevedo-Lopez(1), T. Wilson(2), P. Valderrama(2), D. Rodrigues(1); (1)The University of Texas at Dallas, Richardson, TX, (2)North Dallas Dental Health, Dallas, TX

  • 2:45 p.m. 31. Synthetic Morphogen Fields for Directed Differentiation of Dental Stem Cells, P Arany*, S Rahman; University at Buffalo, Buffalo, NY

Drug Delivery

Timeslot: Wednesday, April 11, 2018 - 1:00pm to 3:00pm
Track: Drug Delivery
Room: Grand Ballroom D


The Drug Delivery SIG session will consider abstracts that fall with the broad areas of therapeutic development, formulation, and application testing. Drug delivery from medical devices, tissue engineering scaffolds/hydrogels, films, microparticles, nanoparticles, environmentally responsive materials, and other types of biomaterial assemblies are all invited. Studies testing drug targeting, drug combinations, and drug/cell combinations are all also welcomed to submit. Drug delivery application areas of interest include but are not limited to regenerative medicine/tissue engineering, cell and tissue transplant, cardiovascular stents and other devices, cancer, microbial infection, and autoimmune diseases.


  • 1:00 p.m. 16. Visceral adipose tissue macrophage-targeted gene delivery for treating obesity-induced type II diabetes, Y Song*, S Yong, H Wee, J Chung, Y Kim; Hanyang University, Seoul, Republic of Korea

  • 1:15 p.m. 17. Tuning Hydrophobe Density and Length in an Anionic Polymer for Enhanced Intracellular Delivery of a CPP-based MAPKAP Kinase II Inhibitor, E. Dailing*, K. Kilchrist, B. Evans, C. Duvall; Vanderbilt University, Nashville, TN

  • 1:30 p.m. 18. Refilling Drug-Eluting Depots through Systemic Administration of Inert Prodrugs, Y. Brudno*(1), B. Kwee(2), N. Joshi(2), M. Aizenberg(3), D. Mooney(2); (1)North Carolina State University, Raleigh, NC, (2)Harvard University, Cambridge, MA, (3)Wyss Institute, Cambridge, MA

  • 1:45 p.m. 19. Influence of Formulation on Cyclodextrin Retention and Drug Delivery for Gastrointestinal Luminal Wound Healing, N. Rohner*(1), S. Merritt(1), S. Zuckerman(1), S. Schomisch(1), J. Marks(2), H. von Recum(1); (1)Case Western Reserve University, Cleveland, OH, (2)University Hospitals Cleveland Medical Center, Cleveland, OH

  • 2:00 p.m. 20. Evaluation of Bone Forming Potential of Simvastatin-containing Polymeric Prodrugs, N Venkatesan*, A Liyanage, J Castro-Núñez, T Asafo-Adjei, T Dziubla, L Cunningham, D Puleo; University of Kentucky, Lexington, KY

  • 2:15 p.m. 21. RhoA knockdown by PgP/siRhoA polyplexes reduces secondary injury in a rat TBI model, C Macks*(1), S Gwak(1), D Jeong(1), M Lynn(2), J Lee(1); (1)Clemson University, Greenville, SC, (2)Greenville Hospital System, Greenville, SC

  • 2:30 p.m. 22. Engineered Controlled Macromolecular Delivery Scaffold for Rotator Cuff Repair, A. Prabhath*(1), V. Vernekar(2), S. Kumbar(2), C. Laurencin(2); (1)University of Connecticut, Storrs, CT, (2)UConn Health, Farmington, CT

  • 2:45 p.m. 23. Development of a Novel Topical Controlled Release System for Otic Drug Delivery, L Bruk*, M Fedorchak; University of Pittsburgh, Pittsburgh, PA

Engineered Microenvironments in to Model Disease

Timeslot: Wednesday, April 11, 2018 - 1:00pm to 3:00pm
Track: Wound Healing and Cellular Microenvironment
Room: 208/209


Biomaterials have been invaluable tools for understanding how cells respond to their microenvironment in both health and disease. Here, we invite contributions that develop biomaterial platforms for cell culture or tissue engineering. Session topics include the following: understanding of the mechanisms that determine cellular responses to disease/injury, determining how biophysical and biochemical cues alter cellular behavior in 3D, identifying differences between 2D and 3D microenvironments in mediating cellular phenotype or response to treatment, developing complex tissue microstructures/organioids, culturing multiple types of cells within complex microenvironments, driving or enriching specific populations, developing improved approaches for utilization of patient derived or difficult to culture cells, drug screening within engineered microenvironments, and engineering microenvironments for therapeutic purposes.


  • 1:00 p.m. 32. Recapitulating the 3D Microenvironment of the Human Neural Microinterface with the Blood Brain Barrier, S Ahn*, J Yom, C Hovell, Y Sei, Y Kim; Georgia Institute of Technology, Atlanta, GA

  • 1:15 p.m. 33. Electrospun fibrillar biomaterial platforms with tunable mechanics as fibrosis disease models, M. Davidson*, K. Song, M. Lee, J. Llewellyn, R. Wells, J. Burdick; University of Pennsylvania, Philadelphia, PA

  • 1:30 p.m. 34. Matrix Elasticity Defines Cell Migration Modes in Aligned Fibrous Microenvironments, W. Wang*, C. Davidson, B. Baker; University of Michigan, Ann Arbor, MI

  • 1:45 p.m. 35. Non-Invasive Oxygen Monitoring Using Fluorescent Hydrogel Microparticles, R. Wilson*, K. Grande-Allen; Rice University, Houston, TX

  • 2:00 p.m. 36. On Chip Reconstitution of Atherogenic Microenvironment Reveals Frequency-Dependent Endothelial Response, Y. Sei*, S. Ahn, T. Virtue, T. Kimg, Y. Kim; Georgia Institute of Technology, Atlanta, GA

  • 2:15 p.m. 37. Engineering Cardiac Tissue Mimics as In Vitro Test Beds to Investigate Congenital Heart Disease, D. Bousalis*(1), C. Lacko(1), R. Wachs(2), H. Kasahara(1), C. Schmidt(1); (1)University of Florida, Gainesville, FL, (2)University of Nebraska-Lincoln, Lincoln, NE

  • 2:30 p.m. 38. Biomimetic Microfluidic Networks in Synthetic and Natural Hydrogels for Vessel-on-a-Chip Applications, K. Keller, J. Sperduto, J. Slater*; University of Delaware, Newark, DE

  • 2:45 p.m. 39. Metabolically-Driven Maturation of iPS-Cell Derived Cardiomyocytes in Microphysiological Systems, N Huebsch*, B Charrez, B Siemons, K Onishi, S Boggess, F Montiel, N Deveshwar, N Jeffries, A Stahl, E Miller, K Healy; University of California, Berkeley, CA

Fabrication and 3D Printing of Tissue Engineering

Timeslot: Wednesday, April 11, 2018 - 1:00pm to 3:00pm
Track: Biomaterials Fabrication and Analysis
Room: 204/205


The field of tissue engineering relies extensively on the use of 3D scaffolds to provide the appropriate microenvironment for tissue regeneration. This session will focus on the state-of-the-art technologies including 3D printing and related methods in the development of biomimetic materials and scaffolds and the application of these scaffolds to modulate desirable cellular responses and various tissue regeneration.


  • 1:00 p.m. 1. Nanoengineered Ionic-Covalent Entanglement Reinforced Bioinks for 3D Bioprinting, D Chimene*, C Peak, J Gentry, J Carrow, L Cross, E Mondragon, G Cardoso, R Kaunas, A Gaharwar; Texas A&M University, College Station, TX

  • 1:15 p.m. 2. Stem Cell-laden Alginate Microgel Bioink for 3D Bioprinting, O. Jeon*(1), T. Hinton(2), A. Feinberg(2), E. Alsberg(1); (1)Case Western Reserve University, Cleveland, OH, (2)Carnegie Mellon University, Pittsburgh, PA

  • 1:30 p.m. 3. 3D-Painting Porosity: A New Approach to Creating Elevated Porosity Biomaterials via Rapid 3D-Printing, A. Jakus*, N. Geisendorfer, P. Lewis, R. Shah; Northwestern University, Chicago, IL

  • 1:45 p.m. 4. Purified Collagen Bioink for 3D Bioprinting, B Bagley*; Advanced Biomatrix, Carlsbad, CA

  • 2:00 p.m. 5. Reverse Engineered Three dimensional Nerve Construct, R. Dhandapani*, J. Radhakrishnan, S. Sethuraman, A. Subramanian; SASTRA University, Thanjavur, India

  • 2:15 p.m. 6. 3D Bioprinting of Tissue Engineered Vascular Graft with Nanoengineered Colloidal Inks, K. Gold*, R. Dedas, A. Jain, A. Gaharwar; Texas A&M University, College Station, TX

  • 2:30 p.m. 7. Rapid Stereolithography Printing of Human-scale Vascularized Tissue, N Anandakrishnan*, H Ye, C Zhou, R Zhao; University at Buffalo, Buffalo, NY

  • 2:45 p.m. 8. 3D Printing A Collagen Heart Valve Using Freeform Reversible Embedding of Suspended Hydrogels, A Hudson*, T Hinton, A Feinberg; Carnegie Mellon University, Pittsburgh, PA

Panel: Contemporary Biomaterials' Ethics: Fundamentals, Recent Issues, and Controversial Case Studies

Timeslot: Wednesday, April 11, 2018 - 1:00pm to 3:00pm
Track: Thought Leaders/Ethics
Room: Grand Ballroom A


Ethics is a critical, pervasive and ongoing issue for the biomaterials' research and clinical community which traditionally has not received much attention at SFB Annual Meetings. The Past SFB President's Advisory Committee was charged in the past to provide guidance to SFB for policies and education in ethics. Based on a successful symposium in 2017 on ethics, this session will highlight case studies which bring biomaterials' ethics to the forefront, discussing a framework and guidance for making decisions. It will also discuss the formulation of an SFB Code of Ethics and generate an SFB ethics agenda for the future of the Society.

Invited Speaker(s)

  • Aaron D. Levine, PhD
  • James Curtis, PhD
  • Luke Brewster, PhD
  • Andres J. García, PhD, FBSE
  • Frederick J. Schoen, MD, PhD, FBSE

Panel:Biomaterial Based Regenerative Medical Product Commercialization hurdles

Timeslot: Wednesday, April 11, 2018 - 1:00pm to 3:00pm
Track: Career and Commercialization
Room: Grand Ballroom B


During the 2017 "Biomaterials and Medical Products Commercialization" Panel Discussions, some concerns were brought about the inconsistency in the common understanding between the Regulatory Agency (FDA), and the Reimbursement Agency (Medicare). It may be due the gap created by inadequate transfer of technical knowledge of such advanced biomaterial based devices. Specifically, in "biological skin substitutes", Medicare (Center for Medicare and Medicaid Services) needs more guidance on Biomaterial sciences with respect to their reimbursement methods and assigning commercial values. However, we understand Medicare has its own limitations. There comes the duty of the Members of the Society for Biomaterials. SFB should take efforts to bring a common understanding in this matter. The Chair and the other panel members all from have also voiced their concerns in the need of a better co-ordination between the regulatory Organizations like FDA, Medicare, and the Medicare's advisory entities such as the American Medical Association or the American Surgeons Association along with the Biomaterial Scientists. The purpose of the 2018 Group Panel Discussion is to enhance the awareness of the problem by increasing the number of Attendees and Scientific papers from the Device Industries, FDA, Medicare, and AMA which guide the CMS. In addition, the other Private and Government payers can participate for their unified understanding about advanced Biomaterials and their commercial valuation. The lead speakers consist of an Officer from CDRH, FDA (Dr. Sussman), an experienced biomaterials Scientist specialized in tissue regenerative products (Dr. Gunasekaran), a Gynecologist having experience in medical product usage and distribution thorough the Hospital Supply Chain system (Dr. Cox) and the end user of regenerative products who is the current President of Georgia Podiatric Medical Association (Dr. Gupta).


  • Our intention is to castigate and arrive at a solution for the following Hurdles:

  • 1. Clinician's failure to understand the biomaterial science to define a bio medical device. This causes clinicians to mis-judge a quality product.

  • 2. Lack of communication between the device using clinicians and the payers resulting in delay or insufficient payments to the services rendered by the clinicians.

  • 3. Improper valuation of a biomaterial device due to lack of biomaterial knowledge by the CMS.

  • 4. The need for Biomaterial Science is ignored during the "decision tree process" of Medicare to evaluate a product, example the skin-substitutes doesn't seem to have adequate scientific definition by CMS.

  • 5. Medical coding and billing methods are quite complicated which confuses the clinicians.

  • 6. Coding and billing methods are devised mainly by some Medical Associations without any feedback or involvement from the Society for Biomaterials that results in poor recognition and valuation of a product.

Invited Speaker(s)

  • Eric Sussman, PhD
  • Subra Gunasekaran, PhD
  • Rupal P. Gupta, DPM, FACFAS
  • Christopher Cox, MD